Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wall Street Zen

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Sunday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. HSBC raised their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Cantor Fitzgerald lifted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Finally, Guggenheim increased their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $802.18.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $798.17 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $82.18 billion, a PE ratio of 19.73, a PEG ratio of 1.54 and a beta of 0.20. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34. The business has a 50-day simple moving average of $769.53 and a two-hundred day simple moving average of $720.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the firm posted $12.81 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Tidal Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 10.7% in the 2nd quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock valued at $27,371,000 after acquiring an additional 4,244 shares in the last quarter. National Pension Service boosted its stake in Regeneron Pharmaceuticals by 2.2% during the second quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock worth $236,830,000 after acquiring an additional 8,264 shares in the last quarter. Krensavage Asset Management LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% during the second quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company’s stock worth $3,741,000 after acquiring an additional 2,000 shares in the last quarter. Engineers Gate Manager LP boosted its stake in Regeneron Pharmaceuticals by 4,309.4% during the second quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company’s stock worth $9,926,000 after acquiring an additional 15,557 shares in the last quarter. Finally, Cidel Asset Management Inc. grew its holdings in Regeneron Pharmaceuticals by 7.8% in the second quarter. Cidel Asset Management Inc. now owns 775 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 56 shares during the period. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.